lives.” 8 The organization publishes the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) that serve as established measures for appropriate disease management in the oncology community. The guidelines also influence the Centers for
Search Results
Anne A. Eaton, Camelia S. Sima, and Katherine S. Panageas
Barbara Todaro
despite appropriate antiemetic treatment or requires additional antiemetic rescue medications. Breakthrough CINV continues to be a concern because it can be difficult to treat. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for
Robert W. Carlson, Jillian L. Scavone, Wui-Jin Koh, Joan S. McClure, Benjamin E. Greer, Rashmi Kumar, Nicole R. McMillian, and Benjamin O. Anderson
. 19 The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) are a comprehensive set of evidence-based, consensus-driven guidelines for delivering multidisciplinary cancer care across the continuum, from risk assessment through prevention
Abdul-Rahman Jazieh, Hanaa Bamefleh, Ahmet Demirkazik, Rabab Mohamed Gaafar, Fady B. Geara, Mansur Javaid, Jamal Khader, Kian Khodadad, Walid Omar, Ahmed Saadeddin, Hassan Al Sabe, Mohammad Behgam Shadmehr, Amgad El Sherif, Najam Uddin, Mohammad Jahanzeb, and David Ettinger
step toward addressing them. Methodology As a part of the initiative to adapt the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Non–Small Cell Lung Cancer 11 to the MENA region, a lung cancer guidelines committee was
Archie Bleyer
Background In this past spring of 2012, 2 new sets of NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) were published directed at the adolescent and young adult (AYA) population with cancer: those for Adolescent and Young Adult
Anal Carcinoma, Version 2.2012
Featured Updates to the NCCN Guidelines
Al B. Benson III, J. Pablo Arnoletti, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Raza A. Dilawari, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, James W. Fleshman Jr., Charles S. Fuchs, Jean L. Grem, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr., Constantinos T. Sofocleous, Alan P. Venook, Christopher Willett, and Deborah A. Freedman-Cass
and management of squamous cell anal carcinoma, which represents the most common histologic form of the disease, are addressed in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Anal Carcinoma (the NCCN Guidelines are available
Edward C. Li and Jessica DeMartino
readily integrated into the current NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) development process. The development of the scoring tools for the CTI would be modeled after the methods stated in the FDA's guidance for developing patient
Neelima Denduluri, Debra A. Patt, Yunfei Wang, Menaka Bhor, Xiaoyan Li, Anne M. Favret, Phuong Khanh Morrow, Richard L. Barron, Lina Asmar, Shanmugapriya Saravanan, Yanli Li, Jacob Garcia, and Gary H. Lyman
Background The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) recommend a wide variety of myelosuppressive chemotherapy regimens for the treatment of cancer in adjuvant and neoadjuvant settings. 1 – 7 Neutropenia is one of
Omalkhair Abulkhair, Nagi Saghir, Lobna Sedky, Ahmed Saadedin, Heba Elzahwary, Neelam Siddiqui, Mervat Al Saleh, Fady Geara, Nuha Birido, Nadia Al-Eissa, Sana Al Sukhun, Huda Abdulkareem, Menar Mohamed Ayoub, Fawaz Deirawan, Salah Fayaz, Alaa Kandil, Sami Khatib, Mufid El-Mistiri, Dorria Salem, El Siah Hassan Sayd, Mohammed Jaloudi, Mohammad Jahanzeb, and William I. Gradishar
pathologist. The committee members reviewed the 2009 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Breast Cancer and suggested modifications suitable to the region. These modifications were discussed among the group members and with a
Carrie Zornosa, Jonathan L. Vandergrift, Gregory P. Kalemkerian, David S. Ettinger, Michael S. Rabin, Mary Reid, Gregory A. Otterson, Marianna Koczywas, Thomas A. D'Amico, Joyce C. Niland, Rizvan Mamet, and Katherine M. Pisters
, selection of first-line therapy is a critical decision point in the treatment of advanced lung cancer. The oncology provider must balance toxicity, expected survival benefit, and impact on quality of life. The NCCN Clinical Practice Guidelines in Oncology
